(600062)"China Resources Double-Crane Pharmaceutical Co., Ltd."Announcement on Progress in Major Asset Restructuring
Filed with SSE · Stock code 600062 · · 2 pages · Chinese
China Resources Double-Crane Pharmaceutical Co., Ltd. on 6ix
Story so far
- Announcement on Propranolol Hydrochloride Injection of the Wholly-owned Subsidiary China Resources Zizhu Pharmaceutical Co., Ltd. Passing the Consistency Evaluation of Quality and Efficacy for Generic Drugs
- Announcement on Obtaining the Drug Registration Certificate for Ezetimibe and Atorvastatin Calcium Tablets by the Wholly-owned Subsidiary China Resources Saike Pharmaceutical Co., Ltd.
- Announcement on Obtaining the Drug Registration Certificate for Lomustine Capsules
Earlier from China Resources Double-Crane Pharmaceutical
- Announcement on Propranolol Hydrochloride Injection of the Wholly-owned Subsidiary China Resources Zizhu Pharmaceutical Co., Ltd. Passing the Consistency Evaluation of Quality and Efficacy for Generic Drugs
- Announcement on Obtaining the Drug Registration Certificate for Ezetimibe and Atorvastatin Calcium Tablets by the Wholly-owned Subsidiary China Resources Saike Pharmaceutical Co., Ltd.
- Notice on Convening the 2nd Extraordinary General Meeting in 2026
- Announcement on Obtaining the Drug Registration Certificate for Lomustine Capsules
- Announcement on the Obtaining of the Drug Registration Certificate for Oxcarbazepine Tablets by the Controlled Subsidiary, China Resources Double-Crane Xiangzhong Pharmaceutical (Hunan) Co., Ltd.
Later from China Resources Double-Crane Pharmaceutical
- Announcement on Obtaining the Approval Notice for Marketing Application of the Chemical API Brexpiprazole by the Controlled Subsidiary China Resources Double-Crane Xiangzhong Pharmaceutical (Hunan) Co., Ltd.
- (600062)"China Resources Double-Crane Pharmaceutical Co., Ltd."Announcement on Obtaining the Approval Notice for Marketing Application of the Chemical API Vortioxetine Hydrobromide by the Controlled Subsidiary China Resources Double-Crane Xiangzhong Pharmaceutical (Hunan) Co., Ltd.
- (600062)"China Resources Double-Crane Pharmaceutical Co., Ltd."Announcement on Obtaining U.S. FDA Clinical Trial Approval for DC7001A Capsules by Wholly-owned Subsidiary Beijing Double-Crane Runchuang Technology Co., Ltd.
- (600062)"China Resources Double-Crane Pharmaceutical Co., Ltd."Announcement on Mycophenolate Mofetil for Injection of the Wholly-owned Subsidiary Double-Crane Pharmaceutical (Hainan) Co., Ltd. Passing the Consistency Evaluation of Quality and Efficacy for Generic Drugs
- (600062)"China Resources Double-Crane Pharmaceutical Co., Ltd."Announcement on Obtaining the Drug Registration Certificate for Composite Potassium Hydrogen Phosphate Injection by the Wholly-owned Subsidiary Anhui Double-Crane Pharmaceutical Co., Ltd.
Follow China Resources Double-Crane Pharmaceutical into a list and get an email when it puts out news.
Follow China Resources Double-Crane Pharmaceutical